Skip to main content

India needs improved diabetes therapies that are affordable and accessible to all: ISCR

Recognizing the crucial need for early screening to detect type 2 diabetes and manage the risk of its serious complications, 'Eyes on Diabetes' is this year's theme for World Diabetes Day which falls on November 14, 2016. While globally there are new and improved therapies to better manage diabetes, these therapies are either expensive or not accessible to the population at large in India, says the Indian Society for Clinical Research (ISCR). 

Therefore, we need to scale-up clinical research, specifically in type 2 diabetes, to provide treatment options that are effective, affordable and improve the quality of a diabetic's life.

"Currently available treatment for diabetes has its limitations in terms of safety and efficacy in achieving glycemic control on long term basis and there is a need for exploring better treatment options, which is only possible through clinical research. Indians differ from other populations in terms of body build, genetic origin, and disease presentation. Hence, India needs more clinical trials in diabetes to develop more suitable and effective treatment options for the Indian population," said Dr. Vyankatesh Shivane, consultant diabetologist & metabolic physician.

It is estimated that by 2030, there will be more than 100 million patients living with diabetes in India. With the growing burden of diabetes in India, there will be a corresponding increase in diabetes related complications, many of which can be managed if the condition is detected on time. According to the International Diabetes Federation, diabetes is a leading cause of cardiovascular disease, blindness, amputation and kidney failure. Data from the International Diabetes Federation indicates that one in two adults with diabetes is undiagnosed and up to 70 per cent of type 2 diabetes cases can be prevented or delayed by adopting healthier lifestyles.

Comments

Popular posts from this blog

BE guidelines regarding investigator

BE guidelines recommend investigator should possess appropriate medical qualification, experience for conducting pharmacokinetic studies Can chairperson of EC directly write to sponsor to clarify some of the queries of clinical trial raised in EC meeting? Dr. Sreevatsa Please see an extract from FDA's comment on IRB-sponsor relationship. The interrelationship and interaction between the research sponsor (e.g., drug, biologic and device manufacturers), the clinical investigator and the Institutional Review Board (IRB) may be very complex. The regulations do not prohibit direct sponsor-IRB contacts, although, the sponsor-IRB interaction customarily occurs through the investigator who conducts the clinical study. The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and FDA-1572, respectively, for drug and biologic studies or a...

Combination Vaccine for Kids withdrawn

A vaccine that combines conventional MMR (Measles, Mumps, Rubella) with Chikenpox has been withdrawn in the United States due to a higher rate of seizures in children. In a study children aged 12 to 23 months who received the combined MMR cum Chickenpox vaccine had double the rate of seizures compared to children who got separate vaccine for MMR and chickenpox. This equates to one additional case of convulsion per 2000 vaccinations.

India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022

Market Research Future published a Statistic research report on India Contract Research Organization Market, from 2017 to 2022″ – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. ​ India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022. In India contract research organization market, drug development/clinical trials accounted for the largest market share in 2016. A Contract Research Organization (CRO) is a service association that offers help to the pharmaceutical business and offers an extensive variety of outsourced pharmaceutical research administrations to help in R&D system and in this way a basic tool for undertaking clinical trials in the present situation when high stakes are included in the drug discovery process. This industry likewise offers a safe choice of venture as the business is to a great extent recession-proof, with a critical upscale development. Get a sample ...